I have capitalized on the breadth of research being conducted in the fields of stem cell research and imaging within this center, and now possesses an extremely unique skill-set in stem cell biology, classic cell/molecular biology, and multi-modality non-invasive imaging technologies (positron emission tomography [PET], dynamic contrast-enhanced computed tomography [DCE-CT], high frequency 3D ultrasound [HFU], and optical [bioluminescence]). Excitingly, I am currently one of few Canadian researchers poised to take full advantage of the recent opening of the PETtracer Cyclotron and PET-radiochemistry facility in London.
My future research goal is to develop a collaborative research program in Molecular and Functional Imaging, in which I will play a lead role in cutting-edge research that focuses on the development of therapeutics for neuromuscular diseases, and on the non-invasive assessment of such therapies.
Dr. Hoffman obtained her Ph.D. from the University of Saskatchewan in 2000. She went on to complete several postdoctoral positions that culminated in a unique skill set in stem cell biology, classic cell/molecular biology, and non-invasive multi-modality imaging.
Imaging modalities include positron emission tomography [PET], dynamic contrast-enhanced computed tomography [DCE-CT], high frequency 3D ultrasound [HFU]/echocardiography, and optical/bioluminescense imaging. She is currently one of few Canadian researchers poised to take advantage of the recent opening of the PETtracer Cyclotron and PET-radiochemistry facility in London.
Dr. Hoffman was appointed as a Lawson Imaging Scientist in the Fall of 2009, and as Assistant Professor in the Departments of Medical Biophysics, Western University (Fall 2009) and Anatomy & Cell Biology, Western University (Spring 2010). Capitalizing on the breadth of her multidisciplinary experience, Dr. Hoffman's current research interests lie in Molecular Imaging and Cell Therapeutics for the treatment of both the skeletal and cardiac manifestations of Duchenne muscular dystrophy (DMD). Specifically, her group aims to develop objective and quantitative non-invasive imaging technologies to track stem/progenitor cell fate following transplantation into mouse models of DMD.